CancerCare is a leading national organization dedicated to providing free support services and financial assistance to anyone affected by cancer. 800-813-HOPE
New York, New York
Joined April 2009
- Tweets7.8K
- Following1.6K
- Followers20.7K
- Likes2.5K
Pinned Tweet
Last year, @CancerCare provided 150,508 services to people diagnosed with cancer, caregivers and bereaved individuals. Our emotional, practical and financial support programs continued to offer help and hope to anyone affected by cancer.
Learn more at cancercare.org.
CancerCare retweeted
New in @Forbes: Sally Pipes cites research from Pioneer and @CancerCare finding 340B hospitals spent an average of 2.16% of operating expenses on charity care vs. 2.82% for non-340B hospitals. Read it here: bit.ly/4sdBqgK 🔒
CancerCare retweeted
#340B reform must be a priority to improve access to healthcare for cancer patients, according to Kim Czubaruk of @CancerCare in a new opinion. Congress should take action to improve 340B transparency and accountability so patients benefit. Read more in @RealClearHealth: realclearhealth.com/articles…
CancerCare retweeted
FDA has granted accelerated approval of an immunotherapy for adults with previously untreated stage II or III locally advanced rectal cancer whose tumors are dMMR or MSI-H.
In a phase 2 study, almost three-fourths of patients did not need surgery, radiotherapy, or chemotherapy after a median follow-up of more than 2 years. For eligible patients, treatment may help avoid chemotherapy, radiation and surgery and their lasting effects.
This is the 11th approval under the Commissioner’s National Priority Voucher pilot program.
ALT Illustration showing two cells representing immunotherapy interacting, with a small inset image of a highlighted colon. Text states: "FDA grants accelerated approval of immunotherapy for certain patients with rectal cancer.
CancerCare retweeted
📋 New post-transplant GvHD symptom tracker
Record your symptoms and track changes over time with our downloadable tracker.
💻 Complete digitally
🖨️ Or print and fill it in by hand
👩⚕️ Share with your healthcare team to help identify patterns or changes.
🔗 Download the tracker here: bit.ly/4jfm4pG
#GvHD
Independently supported by Therakos. Funders are allowed no influence.
FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
fda.gov/drugs/resources-info…
CancerCare retweeted
Big news for bladder cancer patients! FDA just expanded approval of Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only NMIBC — the first treatment approved for this group. This is a first, and that matters. Evidence from a closely related form of bladder cancer supported the approval.
fda.gov/drugs/resources-info…
ALT The image announces that the FDA has approved the first treatment for patients with BCG-unresponsive bladder cancer. It features a purple and orange awareness ribbon and the FDA logo.
CancerCare retweeted
Proud to have our CEO @AnjeeDavis at the 2026 @MilkenInstitute Patient Advocacy Forum in Washington, DC, where she spoke on "Patient Advocacy in the Age of AI, Data, and Digital Trust" about keeping AI-enabled health information accurate, trusted, and grounded in lived experience.
It was great to connect with fellow cancer advocates @JulieFleshman, CEO of @PanCAN, and Christine Verini, RPh, CEO of @CancerCare, who share our commitment to putting patients first. Thank you to the Milken Institute for bringing us together! 💙
Access to trustworthy information matters. Find colorectal cancer resources for patients and families at fightcrc.org/resources.
CancerCare retweeted
News: Today, the @FDA approved a maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer.
fda.gov/drugs/resources-info…
ALT An FDA social media graphic showing a person holding a pink breast cancer awareness ribbon against a light background. Text reads: "FDA approves a maintenance treatment for HER2-positive breast cancer." The FDA logo appears in the bottom right corner.
CancerCare retweeted
Submit your questions to our Ambassadors!
Do you have a question about living with acute myeloid leukemia (AML) or caring for someone with AML that you’d like to ask other patients, caregivers, or healthcare professionals?
We’re hosting a Know AML Ambassadors Meeting on October 22, 2026, and we want to hear from you.
This is your opportunity to submit questions about the experiences, challenges, or practical aspects of AML that you’d like our Ambassadors to discuss.
Share your questions:
- In the comments
- By direct message
- Anonymously via the form here: forms.cloud.microsoft/e/EYeH…
Selected questions will be discussed in the meeting, and a recording will be shared on the Know AML website to support the wider AML community.
#KnowAML #Leukemia #BloodCancer
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL @EliLillyandCo
investor.lilly.com/news-rele…
CancerCare retweeted
“A discount this big shouldn’t be a mystery.” A new @CancerCare & @PioneerPolicy study of nearly 4,000 hospitals finds that #340B hospitals spend less on charity care than hospitals that don’t participate in the program. This research reinforces the need for greater transparency in 340B to ensure the program serves patients. Read more: cancercare.org/press/release…
Join our partners @_KNOW_ALL this Wednesday for a free webinar on support for older adults living with ALL.
Register here: webinar.know-alleukemia.com/…
CancerCare retweeted
New study I co-authored, released by @PioneerPolicy and @CancerCare : 340B hospitals spent 2.16% of operating expenses on charity care vs. 2.82% at non-340B hospitals.
Patients deserve accountability.
pioneerinstitute.org/who-ben…
CancerCare retweeted
🚨BREAKING @FDA News🚨
The FDA has approved belzutifan plus lenvatinib for the treatment of patients with advanced renal cell carcinoma with a clear cell component following treatment with PD-1 or PD-L1 inhibitor.
Full details here ➡️: onclive.com/view/fda-approve…
#kcsm #oncology
CancerCare retweeted
Today, the FDA approved a treatment for advanced renal cell carcinoma. fda.gov/drugs/resources-info…
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
fda.gov/drugs/resources-info…
It’s here! Today is World ALL Day!
On this day, we come together as a global community to raise awareness of acute lymphoblastic leukemia (ALL) and stand with every patient, caregiver & family affected.
Join the global campaign: know-alleukemia.com/world-al…
@_KNOW_ALL
#KnowALL
CancerCare retweeted
Today, we approved a treatment for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This approval gives some people with advanced breast cancer whose tumors have a specific genetic mutation another treatment option. fda.gov/drugs/resources-info…
CancerCare retweeted
Save the date!
Wednesday, September 30 | 16:00 (BST)
Join the Know ALL patient webinar on Wednesday, September 30, for a conversation about personalized treatment, wellbeing, and support for older adults living with acute lymphoblastic leukemia.
Register via the link in our comment below.
This #ThyroidCancerAwarenessMonth, hear how thyroid cancer (TC) survivor Becky and her husband, Michael, navigated the changes that came from her treatment and discovered a recipe they continue to enjoy today. Watch Becky’s story and try her recipe: bit.ly/4d1jIYc
#ad